Search

PRISMA (PRecursore IperSpettrale della Missione Applicativa) is a demonstrative spaceborne mission, fully deployed by the Italian Space Agency (ASI). To support the calibration/validation activities of the PRISMA hyperspectral mission, ASI and the National Research Council (CNR) started in 2019 the PRISCAV project (Scientific CAL/VAL of PRISMA mission). The main objective of PRISCAV is the comprehensive characterization of the performances of the PRISMA payload in orbit in different operational scenarios and the verification of the durability in time of the performances. To this end, PRISCAV created a network of 12 instrumented sites showing different land-use and surface settings (Snow; Sea; Inland and Coastal Water; Forest and Cropland) to obtain independent and traceable in-situ and airborne Fiducial Reference Measurements (FRM) simultaneous to PRISMA acquisitions in order to assess the required performance of sensor, data products, and processors at the different levels (i.e. Top-of-Atmosphere Level 1 Radiances and Bottom-of-Atmosphere Level 2 Reflectance standard products). Moreover, on some of these sites, simultaneous PRISMA and airborne AVIRISNG acquisitions were made coupling remote sensing with in-situ observations to support new mission development and in particular the Copernicus Hyperspectral Imaging Mission for the Environment (CHIME). Recent updates on CAL/VAL activities and on AVIRSNG campaigns are presented in this contribution.

Objective: This paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected by Undifferentiated Systemic AutoInflammatory Diseases (USAIDs). Methods: This is an electronic registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is designed to obtain standardized information for real-life research. The instrument is endowed with flexibility, and it could change over time according to the scientific acquisitions and potentially communicate with other similar tools; this platform ensures security, data quality and data governance. Results: The focus of the AIDA project is connecting physicians and researchers from all over the world to shed a new light on heterogeneous rare diseases. Since its birth, 110 centers from 23 countries and 4 continents have joined the AIDA project. Fifty-four centers have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 179 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry is collecting baseline and follow-up data using 3,769 fields organized into 23 instruments, which include demographics, history, symptoms, trigger/risk factors, therapies, and healthcare information access for USAIDs patients. Conclusions: The development of the AIDA International Registry for USAIDs patients will facilitate the online collection of real standardized data, connecting a worldwide group of researchers: the Registry constitutes an international multicentre observational groundwork aimed at increasing the patient cohort of USAIDs in order to improve our knowledge of this peculiar cluster of autoinflammatory diseases. NCT 05200715 available at https://clinicaltrials

Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). The Registry is a clinical physician-driven non-population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Starting from January 31st, 2021, to February 7th, 2022, 110 centres from 23 countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5993 fields organised into 16 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care. Trial registration NCT05200715 in 21/01/2022. © 2022, The Author(s).

Objective: Aim of this paper is to present the design, construction, and modalities of dissemination of the AutoInflammatory Disease Alliance (AIDA) International Registry for patients with systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still's disease (AOSD), which are the pediatric and adult forms of the same autoinflammatory disorder. Methods: This Registry is a clinical, physician-driven, population- and electronic-based instrument implemented for the retrospective and prospective collection of real-world data. The collection of data is based on the Research Electronic Data Capture (REDCap) tool and is intended to obtain evidence drawn from routine patients' management. The collection of standardized data is thought to bring knowledge about real-life clinical research and potentially communicate with other existing and future Registries dedicated to Still's disease. Moreover, it has been conceived to be flexible enough to easily change according to future scientific acquisitions. Results: Starting from June 30th to February 7th, 2022, 110 Centers from 23 Countries in 4 continents have been involved. Fifty-four of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 290 users (111 Principal Investigators, 175 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 4449 fields organized into 14 instruments, including patient's demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: This international Registry for patients with Still's disease will allow a robust clinical research through collection of standardized data, international consultation, dissemination of knowledge, and implementation of observational studies based on wide cohorts of patients followed-up for very long periods. Solid evidence drawn from “real-life” data represen

Objective: This paper points out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients affected with Undifferentiated Systemic AutoInflammatory Diseases (USAIDs). Methods: This is a physician-driven, population- and electronic-based registry employed for real-world data collection about demographics, clinical, laboratory, instrumental and socioeconomic data of USAIDs patients. Data recruitment, based on the Research Electronic Data Capture (REDCap) tool, is thought to gain standardised information for real-life research and has been developed to change over time according to the scientific acquisitions and potentially communicate with other similar instruments; this platform ensures security, data quality and data governance. Results: The focus of the AIDA project is connecting physicians and researchers from all over the world to shed a new light on heterogeneous rare diseases. Since its birth, 99 centres from 20 countries and 4 continents have joined the AIDA project. Forty-eight centres have already obtained the approval from their local Ethics Committees. Currently, the platform counts 265 users (99 Principal Investigators, 162 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry is collecting baseline and follow-up data using 3357 fields organised into 23 instruments, which include demographics, history, symptoms, trigger/risk factors, therapies, and healthcare access for USAIDs patients. Conclusions: The development of the AIDA International Registry for USAIDs patients will facilitate the on-line collection of standardised data, connecting a worldwide group of researchers: the Registry constitutes an international multicentre observational groundwork aimed at increasing the study cohort of patients with USAIDs in order to improve our knowledge of this peculiar cluster of autoinflammatory diseases.

Objective: Purpose of the present paper is to point out the design, development and deployment of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to pediatric and adult patients with Behçet’s disease (BD). Methods: The Registry is a clinical physician-driven population- and electronic-based instrument implemented for the retrospective and prospective collection of real-life data about demographics, clinical, therapeutic, laboratory, instrumental and socioeconomic information from BD patients; the Registry is based on the Research Electronic Data Capture (REDCap) tool, which is thought to collect standardised information for clinical real-life research, and has been realised to change over time according to future scientific acquisitions and potentially communicate with other existing and future Registries dedicated to BD. Results: Starting from January 31st to November 23rd, 2021, 99 centres from 20 countries in 4 continents have been involved. Forty-eight of these have already obtained the approval from their local Ethics Committees. Currently, the platform counts 265 users (99 Principal Investigators, 162 Site Investigators, 2 Lead Investigators, and 2 data managers). The Registry collects baseline and follow-up data using 5474 fields organised into 15 instruments, including patient’s demographics, history, clinical manifestations and symptoms, trigger/risk factors, therapies and healthcare access. Conclusions: The development of the AIDA International Registry for BD patients will facilitate the collection of standardised data leading to real-world evidence, enabling international multicentre collaborative research through data sharing, international consultation, dissemination of knowledge, inclusion of patients and families, and ultimately optimisation of scientific efforts and implementation of standardised care.

Objective: Aim of this paper is to illustrate the methodology, design, and development of the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to patients with the Periodic Fever, Aphthous stomatitis, Pharyngitis, and cervical Adenitis (PFAPA) syndrome. Methods: This is a physician-driven, population- and electronic-based registry proposed to gather real-world demographics, clinical, laboratory, instrumental and socioeconomic data from patients suffering from PFAPA syndrome. Data recruitment is realized through the on-line Research Electronic Data Capture (REDCap) tool. This registry is thought to collect standardized information for clinical research leading to solid real-life evidence. The international scope and the flexibility of the registry will facilitate the realization of cutting-edge study projects through the constant updating of variables - as required by future scientific acquisitions - and the possible merging and transfer of data between current and future registries devoted to this disease. Results: One hundred and twelve centers have already been involved from 23 countries and 4 continents starting from August 24th, 2021, to March 21st, 2022. Fifty-five out of 112 have already obtained the formal approval from their local Ethics Committees. At current, the platform counts 287 users (108 principal investigators, 179 site investigators, 2 lead investigators, and 2 data managers). The registry collects retrospective and prospective data using 3845 fields organized into 24 instruments, including PFAPA patient’s demographics, medical histories, symptoms, triggers/risk factors, therapies, and impact on the healthcare systems. Conclusions: The development of the AIDA International Registry for patients with PFAPA syndrome will enable the on-line collection of standardized data prompting real-life studies through the connection of worldwide groups of physicians and researchers. This project can be found on https://clinicaltrials.gov

Background: Several cardiovascular (CV) risk algorithms are available to predict CV events in the general population. However, their performance in patients with rheumatoid arthritis (RA) might differ from the general population. This cross-sectional multicentre study aimed to estimate the 10-year CV risk using two different algorithms in a large RA cohort and in patients with osteoarthritis (OA). Methods: In a consecutive series of RA patients and matched OA controls without prior CV events, clinical and serologic data and traditional CV risk factors were recorded. The 10-year CV risk was assessed with the Systematic COronary Risk Evaluation (SCORE) and the “Progetto Cuore” algorithms. Results: 1,467 RA patients and 342 OA subjects were included. RA patients were more frequently diabetic (9.9% vs 6.4%; p=0.04) and smokers (20.4% vs 12.5%; p=0.002) but had lower prevalence of obesity (15% vs 21%; p=0.003). Dyslipidaemia was more prevalent in OA (32.5% vs 21.7%; p<0.0001). The 10-year estimated CV risk was 1.6% (95%CI 1.3-1.9) in RA and 1.4% (95%CI 1.3-1.6) in OA (p=0.002) according to SCORE and 6.5% (95%CI 6.1-6.9) in RA and 4.4% (95%CI 3.9-5.1) in OA (p<0.001) according to “Progetto Cuore”. Regardless of the score used, RA patients had a 3- to-4-fold increased 10-year risk of CV events compared to OA subjects. Conclusion: RA patients have a significantly higher 10-year risk of CV events than OA subjects. In addition to effective disease control and joint damage prevention, specific protective measures targeting modifiable traditional CV risk factors should be implemented in RA.

Introduction: This article points out the design, methods, development and deployment of the international registry promoted by the AutoInflammatory Disease Alliance (AIDA) Network with the aim to define and assess paediatric and adult patients with immune-mediated scleritis. Methods: This registry collects both retrospec-tive and prospective real-world data from patients with non-infectious scleritis through the Research Electronic Data Capture (REDCap) tool and aims to promote knowledge and real-life evidence from patients enrolled worldwide; the registry also allows the collection of standardised data, ensuring the highest levels of security and anonymity of patients’ data and flexibility to change according to scientific acquisitions over time. The communication with other similar registries has been also ensured in order to pursue the sustainability of the project with respect to the adaptation of collected data to the most diverse research projects. Results: Since the launch of the registry, 99 centres have been involved from 20 countries and four continents. Forty-eight of the centres have already obtained a formal approval from their local ethics committees. At present, the platform counts 259 users (95 principal investigators, 160 site investigators, 2 lead investigators, and 2 data managers); the platform collects baseline and follow-up data using 3683 fields organised into 13 instruments, including patient’s demographics, history, symptoms, trigger or risk factors, therapies and health care utilization. Conclusions: The development of the AIDA International Registry for patients with non-infectious scleritis will allow solid research on this rare condition. Real-world evidence result-ing from standardised real-life data will lead to the optimisation of routine clinical and therapeutic management, which are currently limited by the rarity of this ocular inflammatory condition.

This work describes a continuous sampling system that has been designed, implemented, and tested for the acquisition of Inherent Optical Properties (IOPs) during field campaigns. The major challenge of the work was to design and build a flow-through housing accounting for the complex sensing geometry of the ECO-VSF3, a backscattering meter, i.e., three sensor heads each of which measures the VSF at three angles. A detailed characterization of the ECO-VSF3 housing in terms of impact of the boundaries and overall system inertia is reported. A key feature of the system design is the possibility to easily detach the IOP package from the flow-through hydraulic circuit and use it in cast mode at fixed stations. This, to the best of authors' knowledge, is the first time the ECO-VSF3 is used in an underway system. Results from the comparison of continuous (Co) and cast (Ca) bb measurements show excellent agreement, with differences not exceeding 7%, thus proving the system to be reliable and highlighting the feasibility for increasing the spatio-temporal sampling of surface observations.

BACKGROUND: The rice weevil Sitophilus oryzae is one of the most important agricultural pests, causing extensive damage to cereal in fields and to stored grains. S. oryzae has an intracellular symbiotic relationship (endosymbiosis) with the Gram-negative bacterium Sodalis pierantonius and is a valuable model to decipher host-symbiont molecular interactions. RESULTS: We sequenced the Sitophilus oryzae genome using a combination of short and long reads to produce the best assembly for a Curculionidae species to date. We show that S. oryzae has undergone successive bursts of transposable element (TE) amplification, representing 72% of the genome. In addition, we show that many TE families are transcriptionally active, and changes in their expression are associated with insect endosymbiotic state. S. oryzae has undergone a high gene expansion rate, when compared to other beetles. Reconstruction of host-symbiont metabolic networks revealed that, despite its recent association with cereal weevils (30 kyear), S. pierantonius relies on the host for several amino acids and nucleotides to survive and to produce vitamins and essential amino acids required for insect development and cuticle biosynthesis. CONCLUSIONS: Here we present the genome of an agricultural pest beetle, which may act as a foundation for pest control. In addition, S. oryzae may be a useful model for endosymbiosis, and studying TE evolution and regulation, along with the impact of TEs on eukaryotic genomes.

Particulate optical backscattering (bbp) is a crucial parameter for the study of ocean biology and oceanic carbon estimations. In this work, bbp retrieval, by the quasi-analytical algorithm (QAA), is assessed using a large in situ database of matched bbp and remote-sensing reflectance (Rrs). The QAA is also applied to satellite Rrs (ESA OC-CCI project) as well, after their validation against in situ Rrs. Additionally, the effect of Raman Scattering on QAA retrievals is studied. Results show negligible biases above random noise when QAA-derived bbp is compared to in situ bbp. In addition, Rrs from the CCI archive shows good agreement with in situ data. The QAA’s functional form of spectral backscattering slope, as derived from in situ radiometry, is validated. Finally, we show the importance of correcting for Raman Scattering over clear waters prior to semi-analytical retrieval. Overall, this work demonstrates the high efficiency of QAA in the bbp detection in case of both in situ and ocean color data, but it also highlights the necessity to increase the number of observations that are severely under-sampled in respect to others environmental parameters

Hybrid lead halide perovskites have been revolutionary in the photovoltaic research field, reaching efficiencies comparable with the most established photovoltaic technologies, although they have not yet reached their competitors’ stability. The search for a stable configuration requires the engineering of the charge extraction layers; in this work, molecular doping is used as an efficient method for small molecules and polymers employed as hole transport materials in a planar heterojunction configuration on compact-TiO2. We proved the viability of this approach, obtaining significantly increased performances and reduced hysteresis on compact titania-based devices. We investigated the photovoltaic performance correlated to the hole transport material structure. We have demonstrated that the molecular doping mechanism is more reliable than oxidative doping and have verified that molecular doping in polymeric hole transport materials leads to highly efficient perovskite solar cells, with long-term stability.

In the last few decades, phytoplankton biomass has been commonly studied from space. However, satellite analysis of non‐algal particles (NAPs), including heterotrophic bacteria and viruses, is relatively recent. In this work, we estimate the backscattering coefficient associated with the NAP fraction that does not covary with chlorophyll based on satellite particulate backscattering coefficient and chlorophyll (bbpNAP). bbpNAP is computed at 100‐km resolution using 19 years of monthly satellite data. We find clear differences in bbpNAP between northern and southern oceans. High bbpNAP values are found in the Arctic and Southern Oceans, the North Atlantic area influenced by the Gulf Stream current, as well as shelf regions (i.e., Patagonian shelf) affected by upwelling regimes. Low correlation between chlorophyll and backscattering prevents precise bbpNAP estimations in oligotrophic areas (e.g., subtropical gyres). These bbpNAP estimations lead to a reduction to half in satellite‐based phytoplankton biomass estimates respect to previously published results.

The introduction of hybrid perovskites is revolutionizing the field of solution processable next-generation optoelectronic devices, with outstanding results achieved in solar energy conversion devices, lasing, light emitting diodes, and thermoelectric generators. An intelligent design of the material properties is a critical element in the technological development of such devices and, to achieve it, excellent control of the material deposition procedures is of paramount importance. Here we compare the growth of hybrid perovskite, starting both from lead iodide and lead chloride, through a simple two-step method on the most widely employed substrates, and we present diverse morphologies, realized varying the substrates and the deposition procedures

Item does not contain fulltext

We adopted a procedure to achieve an optimised CH3NH3PbI3 layer in a planar TiO2 based Planar Heterojunction, which finally results in hysteresis-less and high-efficiency solar cells. We explored the optimisation of the perovskite film thickness, by using a super-saturated solution of CH3NH3I and PbI2 precursors, which also impact on the quality and size of perovskite domains, and the fine-tuning of the perovskite layer surface by a thermal-vacuum post-deposition treatment. Using this procedure, we have obtained a pinhole-free perovskite film with large grain size, reduced surface defects, and generate high photovoltaic performance almost independent on the voltage scan direction. Through photophysical characterization, we proved that the fine setting of the combined thermal-vacuum treatments results in extra-large grains, simultaneously offsetting film defect concentration. Our finding suggests how hysteresis can be efficiently stemmed by simply optimising perovskite processing conditions targeting different device layouts.[1] Moreover, we present a well know p-type doping material as an additive for the Hole Transport Material (HTM), 2,3,5,6-Tetrafluoro-7,7,8,8-tetracyanoquinodimethane, i.e. F4TCNQ: we have tested various doping concentration in the two most used HTM material for perovskite-based solar cells, Spiro-OMeTAD and P3HT, defining the best doping condition and testing stability in months.